阿奇霉素联合头孢三代菌素对小儿支原体肺炎治疗效果 分析(1)
【摘 要】目的：本文就阿奇霉素联合头孢三代菌素治疗小儿支原体肺炎的临床效果进行研究探讨。方法：选取我科在2017年上半年收治的104例小儿支原体肺炎患者，采用随机数字表法对其进行分组，实验组与参照组各52例，为实验组采用阿奇霉素联合头孢三代菌素治疗，参照组单纯予以阿奇霉素治疗，对两组的疗效、症状消退时间进行对比，并观察不良反应。结果：实验组的治疗总有效率高于参照组(98.08%>84.62%)，实验组患儿的退热时间、咳嗽及肺部啰音消失时间均快于参照组，实验组的不良反应发生率对比参照组更低(7.69%<25.00%)，组间比较P<0.05。结论：应用阿奇霉素联合头孢三代菌素治疗小儿支原体肺炎安全又有效，并可加快患儿的症状消退时间，是一种值得推广的治疗方案。
【关键词】阿奇霉素；头孢三代菌素；小儿支原体肺炎；不良反应
Abstract Objective： To study the clinical effect of Azithromycin combined with cephalosporin three generation of Mycoplasma in the treatment of mycoplasma pneumonia in children. Methods： 104 cases of mycoplasma pneumonia in our department in the first half of 2017 were selected to be divided into groups by random digital table， and 52 cases in the experimental group and the reference group. The experimental group was treated with Azithromycin combined with cephalosporin， and the reference group was treated with azythromycin alone. The curative effect and symptoms of the two groups were eliminated. The time was compared and the adverse reaction was observed. Results： the total effective rate of treatment in the experimental group was higher than that of the reference group (98.08%>84.62%). The time of fever and the disappearance of cough and lung rale in the experimental group were faster than those in the reference group. The incidence of adverse reactions in the experimental group was lower than that in the reference group (7.69%<25.00%)， and the comparison between the groups was P< 0.05. Conclusion： the application of Azithromycin combined with cephalosporin in the treatment of mycoplasma pneumonia in children is safe and effective， and can accelerate the withdrawal time of the children's symptoms. It is a kind of treatment scheme worthy of promotion.
Key words： Azithromycin； cephalosporin three generation Mycoplasma； mycoplasma pneumonia in children； adverse reactions
【中圖分类号】R563.13 【文献标识码】B 【文章编号】1672-3783(2018)07-03--01
支原体肺炎是儿科中常见的呼吸系统疾病，也称之为原发性非典型肺炎，是由支原体感染所致[1]。患儿通常是急性发作，表现出发热、咳嗽等症状，如治疗不及时或治疗不当会累及多个器官病变，不利于小儿的成长及发育。为使该类患儿获得更为理想的治疗效果，我科在2017年上半年为其采用阿奇霉素联合头孢三代菌素治疗，现将治疗过程及相关数据汇总如下：
1 一般资料及方法
1.1 一般资料数据
入组者均为我科在2017年1月--6月收治的支原体肺炎患儿，共计104例，入院时均表现有持续发热、剧烈咳嗽等症状，体温超过38℃，为其行常规的实验室检查及影像学检查，符合《诸福棠实用儿科学》中的相关诊断标准[2]。采用随机数字表法对其进行分组，实验组与参照组各52例。实验组中男女患儿分别为25例、27例；年龄分布在2--13岁之间，平均(6.1±1.5)岁；病程在2.5--9d之间不等。参照组中男女患儿分别为28例、24例；年龄分布在2--14岁之间，平均(6.4±1.3)岁；病程在2--9d之间不等。两组患儿对比，在年龄分布、性别比例、病程方面无显著差异，P>0.05。
排除标准：将伴有严重脏器功能损伤、神经系统疾病的患儿予以排除。入组患儿的家长对于本次研究均有知情权，且已经签署好知情同意书。, 百拇医药(蒋华)
【关键词】阿奇霉素；头孢三代菌素；小儿支原体肺炎；不良反应
Abstract Objective： To study the clinical effect of Azithromycin combined with cephalosporin three generation of Mycoplasma in the treatment of mycoplasma pneumonia in children. Methods： 104 cases of mycoplasma pneumonia in our department in the first half of 2017 were selected to be divided into groups by random digital table， and 52 cases in the experimental group and the reference group. The experimental group was treated with Azithromycin combined with cephalosporin， and the reference group was treated with azythromycin alone. The curative effect and symptoms of the two groups were eliminated. The time was compared and the adverse reaction was observed. Results： the total effective rate of treatment in the experimental group was higher than that of the reference group (98.08%>84.62%). The time of fever and the disappearance of cough and lung rale in the experimental group were faster than those in the reference group. The incidence of adverse reactions in the experimental group was lower than that in the reference group (7.69%<25.00%)， and the comparison between the groups was P< 0.05. Conclusion： the application of Azithromycin combined with cephalosporin in the treatment of mycoplasma pneumonia in children is safe and effective， and can accelerate the withdrawal time of the children's symptoms. It is a kind of treatment scheme worthy of promotion.
Key words： Azithromycin； cephalosporin three generation Mycoplasma； mycoplasma pneumonia in children； adverse reactions
【中圖分类号】R563.13 【文献标识码】B 【文章编号】1672-3783(2018)07-03--01
支原体肺炎是儿科中常见的呼吸系统疾病，也称之为原发性非典型肺炎，是由支原体感染所致[1]。患儿通常是急性发作，表现出发热、咳嗽等症状，如治疗不及时或治疗不当会累及多个器官病变，不利于小儿的成长及发育。为使该类患儿获得更为理想的治疗效果，我科在2017年上半年为其采用阿奇霉素联合头孢三代菌素治疗，现将治疗过程及相关数据汇总如下：
1 一般资料及方法
1.1 一般资料数据
入组者均为我科在2017年1月--6月收治的支原体肺炎患儿，共计104例，入院时均表现有持续发热、剧烈咳嗽等症状，体温超过38℃，为其行常规的实验室检查及影像学检查，符合《诸福棠实用儿科学》中的相关诊断标准[2]。采用随机数字表法对其进行分组，实验组与参照组各52例。实验组中男女患儿分别为25例、27例；年龄分布在2--13岁之间，平均(6.1±1.5)岁；病程在2.5--9d之间不等。参照组中男女患儿分别为28例、24例；年龄分布在2--14岁之间，平均(6.4±1.3)岁；病程在2--9d之间不等。两组患儿对比，在年龄分布、性别比例、病程方面无显著差异，P>0.05。
排除标准：将伴有严重脏器功能损伤、神经系统疾病的患儿予以排除。入组患儿的家长对于本次研究均有知情权，且已经签署好知情同意书。, 百拇医药(蒋华)